Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen

Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec) is expected to join the NHI reimbursement list on May 20 with Japan’s highest price tag of 167 million yen, people familiar with the matter have told Jiho. The price...read more